[{"id":"0a1e7551-4f28-4fcb-afa2-2527d2492114","acronym":"","url":"https://clinicaltrials.gov/study/NCT04874844","created_at":"2021-05-06T12:52:59.177Z","updated_at":"2024-07-02T16:36:30.558Z","phase":"Phase 2/3","brief_title":"JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety","source_id_and_acronym":"NCT04874844","lead_sponsor":"Beijing Dongfang Biotech Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib • JY025"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 07/30/2021","start_date":" 07/30/2021","primary_txt":" Primary completion: 03/30/2022","primary_completion_date":" 03/30/2022","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2021-05-10"}]